Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3 clinical trials
A081801 / RLUN20119 / ALCHEMIST-IO (ACCIO) / Yuhchyau Chen  

Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth …

non-squamous non-small cell lung cancer
squamous non-small cell lung carcinoma
lung non-small cell squamous carcinoma
neutrophil count
kaposi sarcoma
  • 0 views
  • 19 Feb, 2024
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor proportion score (TPS) of less than 50%.

squamous non-small cell lung cancer
squamous non-small cell lung carcinoma
adjuvant therapy
non-squamous non-small cell lung cancer
lung cancer
  • 0 views
  • 19 Feb, 2024